Sentiment-Signal
15,5
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Unternehmen & Branche
| Name | TransMedics Group, Inc. |
|---|---|
| Ticker | TMDX |
| CIK | 0001756262 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Medical - Devices |
| SIC | 3845 · Electromedical & Electrotherapeutic Apparatus |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 3,50 Mrd. USD |
| Beta | 2,08 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 605,494,000 | 190,291,000 | 4.87 | 1,068,373,000 | 473,100,000 |
| 2025-09-30 | 10-Q | 143,823,000 | 24,319,000 | 0.66 | 946,032,000 | 355,200,000 |
| 2025-06-30 | 10-Q | 157,370,000 | 34,907,000 | 0.92 | 890,522,000 | 318,101,000 |
| 2025-03-31 | 10-Q | 143,537,000 | 25,682,000 | 0.70 | 837,530,000 | 266,308,000 |
| 2024-12-31 | 10-K | 441,540,000 | 35,464,000 | 1.01 | 804,076,000 | 228,603,000 |
| 2024-09-30 | 10-Q | 108,761,000 | 4,216,000 | 0.12 | 785,571,000 | 209,920,000 |
| 2024-06-30 | 10-Q | 114,305,000 | 12,194,000 | 0.35 | 758,577,000 | 189,894,000 |
| 2024-03-31 | 10-Q | 96,850,000 | 12,197,000 | 0.35 | 723,831,000 | 159,471,000 |
| 2023-12-31 | 10-K | 241,623,000 | -25,028,000 | -0.77 | 706,047,000 | 137,202,000 |
| 2023-09-30 | 10-Q | 66,430,000 | -25,422,000 | -0.78 | 689,227,000 | 126,460,000 |
| 2023-06-30 | 10-Q | 52,465,000 | -1,001,000 | -0.03 | 690,358,000 | 145,213,000 |
| 2023-03-31 | 10-Q | 41,554,000 | -2,636,000 | -0.08 | 287,088,000 | 192,625,000 |
| 2022-12-31 | 10-Q | -36,200,000 | 277,147,000 | 187,375,000 | ||
| 2022-12-31 | 10-K | 93,459,000 | -36,231,000 | -1.23 | 277,147,000 | 187,375,000 |
| 2022-09-30 | 10-Q | 25,683,000 | -7,426,000 | -0.25 | 274,873,000 | 187,857,000 |
| 2022-06-30 | 10-Q | 20,521,000 | -11,523,000 | -0.41 | 117,285,000 | 50,919,000 |
| 2022-03-31 | 10-Q | 15,880,000 | -10,562,000 | -0.38 | 124,008,000 | 59,910,000 |
| 2021-12-31 | 10-K | 30,262,000 | -44,215,000 | -1.60 | 134,893,000 | 67,854,000 |
| 2021-12-31 | 10-Q | -44,200,000 | 134,893,000 | 67,854,000 | ||
| 2021-09-30 | 10-Q | 5,370,000 | -12,962,000 | -0.47 | 131,146,000 | 78,549,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-04 | Lovell Stephanie | Director | Open Market Sale | -1,193 | 149.62 | -178,496.66 | -38,9% | |
| 2026-03-04 | Hernandez Gerardo | Officer, Chief Financial Officer | Open Market Sale | -5,912 | 147.21 | -870,305.52 | -189,9% | |
| 2026-03-04 | Hernandez Gerardo | Officer, Chief Financial Officer | Open Market Sale | -1,324 | 147.21 | -194,906.04 | -42,5% | |
| 2026-03-04 | Weill David | Director | Open Market Sale | -3,571 | 146.82 | -524,294.22 | -114,4% | |
| 2026-03-02 | Corcoran Nicholas | Officer, See remarks | Open Market Sale | -2,966 | 139.12 | -412,629.92 | -90,0% | |
| 2026-03-02 | Hernandez Gerardo | Officer, Chief Financial Officer | Open Market Sale | -375 | 139.12 | -52,170.00 | -11,4% | |
| 2026-03-02 | Ranganath Anil P. | Officer, See remarks | Open Market Sale | -864 | 139.12 | -120,199.68 | -26,2% | |
| 2025-12-04 | Hernandez Gerardo | Officer, Chief Financial Officer | Open Market Sale | -920 | 139.62 | -128,450.40 | -28,0% | |
| 2025-12-03 | Weill David | Director | Open Market Sale | -5,000 | 138.64 | -693,200.00 | -151,3% | |
| 2025-11-25 | Ranganath Anil P. | Officer, See remarks | Open Market Sale | -3,000 | 145.22 | -435,660.00 | -95,1% | |
| 2025-11-17 | Hassanein Waleed H | Director, Officer, President & CEO | Open Market Purchase | 8,775 | 114.00 | 1,000,350.00 | +218,3% | |
| 2025-10-29 | Basile Edward M | Director | Open Market Sale | -4,142 | 130.45 | -540,323.90 | -117,9% | |
| 2025-08-07 | Hassanein Waleed H | Director, Officer, President & CEO | Open Market Purchase | 6,617 | 116.08 | 768,101.36 | +167,6% | |
| 2025-08-07 | Hassanein Waleed H | Director, Officer, President & CEO | Open Market Purchase | 1,858 | 116.85 | 217,107.30 | +47,4% | |
| 2025-08-06 | Hassanein Waleed H | Director, Officer, President & CEO | Open Market Purchase | 8,400 | 118.68 | 996,912.00 | +217,5% | |
| 2025-08-04 | Basile Edward M | Director | Open Market Sale | -4,143 | 125.51 | -519,987.93 | -113,5% | |
| 2025-06-09 | Ranganath Anil P. | Officer, See remarks | Open Market Sale | -686 | 139.80 | -95,902.80 | -20,9% | |
| 2025-05-27 | Basile Edward M | Director | Open Market Sale | -5,000 | 126.45 | -632,250.00 | -138,0% | |
| 2025-05-23 | Weill David | Director | Open Market Sale | -732 | 123.88 | -90,680.16 | -19,8% | |
| 2025-05-09 | Basile Edward M | Director | Open Market Sale | -6,000 | 115.63 | -693,780.00 | -151,4% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.